prostate cancer

[CytoDyn, Inc.] CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.

[British Journal of Cancer] The authors identified homeobox B9 (HOXB9) as a critical regulator of metastatic metastatic prostate CSCs behavior.

[International Journal of Nanomedicine] Scientists investigated whether the conjugation of gold nanocages with the cancer targeting ligand lactoferrin, polyethylene glycol and polyethylenimine could lead to enhanced transfection efficiency on prostate cancer cells in vitro, without assistance of external stimulation.

[Life Sciences] Researchers investigated the role of miR-223-3p in promoting radiotherapy resistance of prostate cancer cells by activating glycolysis.

[Journal of Pathology] Investigators explored markers of autophagy and lipophagy in human prostate cancer tissues in correlation with factors of aggressiveness, and they evaluated the influence of periprostatic adipose tissue adipocytes on autophagy and lipophagy.

[Nature Communications] The authors developed a high-throughput multi-layer functional genomics method called Pooled full-length UTR Multiplex Assay on Gene Expression to quantify the molecular consequences of somatic 5’ UTR mutations in human prostate cancer.